Piper Sandler analyst Jason Bednar maintained a Sell rating on Vapotherm (VAPO – Research Report) today and set a price target of $0.25. The company’s shares closed yesterday at $0.37.
According to TipRanks, Bednar is an analyst with an average return of -4.8% and a 39.36% success rate. Bednar covers the Healthcare sector, focusing on stocks such as NovoCure, Masimo, and Merit Medical Systems.
Vapotherm has an analyst consensus of Hold.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.96 and a one-year low of $0.35. Currently, Vapotherm has an average volume of 250.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. It offers Hi-VNI Technology, a product which delivers noninvasive ventilator support by providing heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. Its products include Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, Precision Flow Heliox, Vapotherm Transfer Unit 2.0, Q50 compressor, Disposable Patient Circuit, Nitric Oxidie Disposable Patient Circuit, Nasal Cannulas, Tracheostomy Adapter and Aerogen Adapter. The company was founded by William F. Niland, Jun Cortez, and William Cirksena in 1998 and is headquartered in Exeter, NH.
